Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors
Open Access
- 19 February 2002
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 99 (4) , 2246-2251
- https://doi.org/10.1073/pnas.042372199
Abstract
Bone marrow is a major homing site for circulating epithelial tumor cells. The present study was aimed to assess the proliferative capacity of occult metastatic cells in bone marrow of patients with operable solid tumors especially with regard to their clinical outcome. We obtained bone marrow aspirates from 153 patients with carcinomas of the prostate (n = 46), breast (n = 45), colon (n = 33), and kidney (n = 29). Most of the patients (87%) had primary disease with no clinical signs of overt metastases [tumor-node-metastasis (TNM)-stage UICC (Union Internationale Contre le Cancer) I-III]. After bone marrow was cultured for 21–102 days under special cell culture conditions, viable epithelial cells were detected by cytokeratin staining in 124 patients (81%). The cultured epithelial cells harbored Ki-ras2 mutations and numerical chromosomal aberrations. The highest median number of expanded tumor cells was observed in prostate cancer (2,619 per flask). There was a significant positive correlation between the number of expanded tumor cells and the UICC-stage of the patients (P = 0.03) or the presence of overt metastases (P = 0.04). Moreover, a strong expansion of tumor cells was correlated to an increased rate of cancer-related deaths (P = 0.007) and a reduced survival of the patients (P = 0.006). In conclusion, the majority of cancer patients have viable tumor cells in their bone marrow at primary tumor diagnosis, and the proliferative potential of these cells determines the clinical outcome.Keywords
This publication has 26 references indexed in Scilit:
- Detection of Cytokeratin-Positive Cells in Bone Marrow in Breast Cancer and Colorectal Carcinoma in Comparison with Other Factors of PrognosisJournal of Hematotherapy & Stem Cell Research, 2000
- Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast CancerNew England Journal of Medicine, 2000
- Identification of expressed genes by laser-mediated manipulation of single cellsNature Biotechnology, 1998
- Individual development and uPA–receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancerNature Medicine, 1995
- Establishment of Micrometastatic Carcinoma Cell Lines: a Novel Source of Tumor Cell VaccinesJNCI Journal of the National Cancer Institute, 1995
- Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-upBritish Journal of Cancer, 1994
- Methodological Analysis of Immunocytochemical Screening for Disseminated Epithelial Tumor Cells in Bone MarrowJournal of Hematotherapy, 1994
- Differential Expression of Proliferation-Associated Molecules in Individual Micrometastatic Carcinoma CellsJNCI Journal of the National Cancer Institute, 1993
- Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patientsThe Lancet, 1992
- Micrometastatic tumour cells in bone marrow of patients with gastric cancer: Methodological aspects of detection and prognostic significanceEuropean Journal of Cancer and Clinical Oncology, 1991